SHIM
CRSP icon

Stone House Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Stone House Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$654 Buy
+12
New +$632 ﹤0.01% 958
2025
Q2 		– Sell
-90
Closed -$3.06K – 532
2025
Q1 		$3.06K Buy
+90
New +$3.81K ﹤0.01% 359
2024
Q4 		– Sell
-460
Closed -$21.6K – 120
2024
Q3 		$21.6K Sell
460
-66
-13% -$3.35K ﹤0.01% 174
2024
Q2 		$28.4K Sell
526
-43
-8% -$2.49K 0.01% 161
2024
Q1 		$38.8K Buy
569
+400
+237% +$28.6K 0.01% 145
2023
Q4 		$10.6K Sell
169
-27
-14% -$1.49K ﹤0.01% 160
2023
Q3 		$8.9K Hold
196
– – ﹤0.01% 169
2023
Q2 		$11K Hold
196
– – ﹤0.01% 155
2023
Q1 		$8.87K Buy
+196
New +$9.52K ﹤0.01% 171

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Stone House Investment Management's CRSP Position: Q2 2026 in Review

Stone House Investment Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 12 shares worth $654. The stake represents ﹤0.01% of the portfolio and ranks #958 among its holdings. This is a return to the name: Stone House Investment Management previously reported a position in CRSP as recently as Q1 2025.

Stone House Investment Management first reported a position in CRSP in Q1 2023 and has held it in 9 quarters since. The position peaked at $38.8K in Q1 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Stone House Investment Management held 12 shares of CRISPR Therapeutics worth $654 as of Q2 2026.
  • CRISPR Therapeutics was a new Stone House Investment Management position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #958 holding.
  • Stone House Investment Management first reported a position in CRISPR Therapeutics in Q1 2023 and has held it in 9 quarters since.
  • Stone House Investment Management's CRISPR Therapeutics position peaked at $38.8K in Q1 2024.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.